Belite Bio, Inc. ADR (BLTE) has released an update.
Belite Bio, Inc. has appointed Dr. Hendrik P. N. Scholl, a world-renowned ophthalmologist, as their new Chief Medical Officer. Dr. Scholl’s extensive experience in retinal diseases, including his role in the largest Stargardt disease study, positions him to advance Belite Bio’s lead drug candidate, Tinlarebant, targeting macular degenerations. This strategic move aims to bolster the company’s commitment to developing treatments for eye conditions with high unmet medical needs.
For further insights into BLTE stock, check out TipRanks’ Stock Analysis page.
